Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-15

Clinical Trial Update: A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial of ABP 654 for moderate to severe plaque psoriasis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABP 654 (adalimumab biosimilar)

Snippet

Sponsor: Amgen | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2023-12-15